Tom Marshall

Tom Marshall

Auto-generated profile, based on publicly available information

Tom Marshall

Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, UK

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2016 in Age and Ageing
Verified
Journal Article
Open access
PDF file
ACAndrew Clegg
Andrew Clegg
CBChris Bates
Chris Bates
JYJohn Young
John Young
RRRonan Ryan
Ronan Ryan
LNLinda Nichols
Linda Nichols
TMTom Marshall
Tom Marshall
Background: frailty is an especially problematic expression of population ageing. International guidelines recommend routine identification of frailty to provide evidence-based treatment, but currently available tools require additional resource. Objectives: to develop and validate an electronic frailty index (eFI) using routinely available primary care electronic health record data. Study design and setting: retrospective cohort study. Development and internal validation cohorts were established using a randomly split sample of the ResearchOne primary care database. External validation cohort established using THIN database. Participants: patients aged 65–95, registered with a ResearchOne or THIN practice on 14 October 2008. Predictors: we constructed the eFI using the cumulative deficit frailty model as our theoretical framework. The eFI score is calculated by the presence or absence of individual deficits as a proportion of the total possible. Categories of fit, mild, moderate and severe frailty were defined using population quartiles. Outcomes: outcomes were 1-, 3- and 5-year mortality, hospitalisation and nursing home admission. Statistical analysis: hazard ratios (HRs) were estimated using bivariate and multivariate Cox regression analyses. Discrimination was assessed using receiver operating characteristic (ROC) curves. Calibration was assessed using pseudo-R2 estimates. Results: we include data from a total of 931,541 patients. The eFI incorporates 36 deficits constructed using 2,171 CTV3 codes. One-year adjusted HR for mortality was 1.92 (95% CI 1.81–2.04) for mild frailty, 3.10 (95% CI 2.91–3.31) for moderate frailty and 4.52 (95% CI 4.16–4.91) for severe frailty. Corresponding estimates for hospitalisation were 1.93 (95% CI 1.86–2.01), 3.04 (95% CI 2.90–3.19) and 4.73 (95% CI 4.43–5.06) and for nursing home admission were 1.89 (95% CI 1.63–2.15), 3.19 (95% CI 2.73–3.73) and 4.76 (95% CI 3.92–5.77), with good to moderate discrimination but low calibration estimates. Conclusions: the eFI uses routine data to identify older people with mild, moderate and severe frailty, with robust predictive validity for outcomes of mortality, hospitalisation and nursing home admission. Routine implementation of the eFI could enable delivery of evidence-based interventions to improve outcomes for this vulnerable group.

13 February 2019 in BMJ
Verified
Journal Article
Open access
PDF file
CTClare J Taylor
Clare J Taylor
JOJosé Manuel Ordóñez-Mena
José Manuel Ordóñez-Mena
ARAndrea K Roalfe
Andrea K Roalfe
SLSarah L. Lay-Flurrie
Sarah L. Lay-Flurrie
NJNicholas R Jones
Nicholas R Jones
FHF D Richard Hobbs
F D Richard Hobbs
Objectives: To report reliable estimates of short term and long term survival rates for people with a diagnosis of heart failure and to assess trends over time by year of diagnosis, hospital admission, and socioeconomic group. Design: Population based cohort study. Setting: Primary care, United Kingdom. Participants: Primary care data for 55 959 patients aged 45 and over with a new diagnosis of heart failure and 278 679 age and sex matched controls in the Clinical Practice Research Datalink from 1 January 2000 to 31 December 2017 and linked to inpatient Hospital Episode Statistics and Office for National Statistics mortality data. Main outcome measures: Survival rates at one, five, and 10 years and cause of death for people with and without heart failure; and temporal trends in survival by year of diagnosis, hospital admission, and socioeconomic group. Results: Overall, one, five, and 10 year survival rates increased by 6.6% (from 74.2% in 2000 to 80.8% in 2016), 7.2% (from 41.0% in 2000 to 48.2% in 2012), and 6.4% (from 19.8% in 2000 to 26.2% in 2007), respectively. There were 30 906 deaths in the heart failure group over the study period. Heart failure was listed on the death certificate in 13 093 (42.4%) of these patients, and in 2237 (7.2%) it was the primary cause of death. Improvement in survival was greater for patients not requiring admission to hospital around the time of diagnosis (median difference 2.4 years; 5.3 v 2.9 years, P<0.001). There was a deprivation gap in median survival of 0.5 years between people who were least deprived and those who were most deprived (4.6 v 4.1 years, P<0.001). Conclusions: Survival after a diagnosis of heart failure has shown only modest improvement in the 21st century and lags behind other serious conditions, such as cancer. New strategies to achieve timely diagnosis and treatment initiation in primary care for all socioeconomic groups should be a priority for future research and policy.

1 August 2019 in The Lancet
Verified
Journal Article
Closed access
GRGholamreza Roshandel
Gholamreza Roshandel
MKMasoud Khoshnia
Masoud Khoshnia
HPHossein Poustchi
Hossein Poustchi
KHKarla Hemming
Karla Hemming
FKFarin Kamangar
Farin Kamangar
RMReza Malekzadeh
Reza Malekzadeh

27 April 2005 in Colorectal Disease
Verified
Journal Article
Closed access
PDF file
ASA. K. A. Samad
A. K. A. Samad
RTR. S. Taylor
R. S. Taylor
TMT. Marshall
T. Marshall
MCM. A. S. Chapman
M. A. S. Chapman

1 January 2006 in Climacteric
Verified
Journal Article
Closed access
PGP. Gupta
P. Gupta
DSD. W. Sturdee
D. W. Sturdee
SPS. L. Palin
S. L. Palin
KMK. Majumder
K. Majumder
RFR. Fear
R. Fear
IPI. Paterson
I. Paterson
Objectives To determine, first, the prevalence and severity of various symptoms related to estrogen deficiency in women within a few years of receiving treatment for breast cancer, second, how women perceive the effects of these symptoms on their quality of life and, third, what measures have been taken to relieve vasomotor symptoms. Methods Two hundred women (aged 29–65 years) who had received treatment for breast cancer within the last 5 years were included in this cross-sectional survey. Information was collected about their breast cancer treatment, menopausal symptoms (Menopausal Rating Scale), the perceived effects of menopausal symptoms on their and their partner's quality of life and any treatments they were receiving for hot flushes. Results All but one woman reported at least one symptom related to the menopause (95.9% vasomotor; 83.3% psychological; 89.7% somatic). Current treatment with tamoxifen or previous chemotherapy did not influence the prevalence or the severity of hot flushes. Current antidepressant treatment was, however, significantly associated with a higher prevalence and severity of most menopausal symptoms, including hot flushes and sweats (p = 0.008). The severity of hot flushes and sweats was significantly correlated with self-assessed effects on overall quality of life (rs = 0.47); 56.4% of the respondents believed that menopausal symptoms had affected their partner's quality of life, the strongest correlations being with severity of sexual symptoms (rs = 0.56) and vaginal dryness (rs = 0.5). Only 21% of women experiencing hot flushes were receiving any treatment for hot flushes, with most women describing no knowledge or poor knowledge of treatment options. Conclusions The majority of women receiving treatment for breast cancer report menopausal symptoms, which negatively correlate, not only with their own, but also with their partner's quality of life. Most women experiencing hot flushes are not receiving treatment due to lack of both awareness and confidence in the existing treatment options.

1 February 2001 in The Lancet
Verified
Journal Article
Closed access
MMMohammed A Mohammed
Mohammed A Mohammed
KCKk Cheng
Kk Cheng
ARAndrew Rouse
Andrew Rouse
TMTom Marshall
Tom Marshall